Company news

Share this article:
A US appeals court upheld a lower court ruling finding the Plavix patent valid, meaning patent protection will be maintained until November 2011. Sanofi-Aventis and Bristol-Myers Squibb are seeking damages from Canadian drug manufacturer Apotex Inc., which launched a generic version of Plavix in 2006. BMS has claimed that it lost as much as $1.75 billion in sales after Apotex's generic version of Plavix hit the market in 2006. Plavix is the world's second biggest drug and the biggest selling product for BMS and second-biggest for Sanofi, behind Lovenox. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.